JPWO2019175776A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019175776A5 JPWO2019175776A5 JP2020548916A JP2020548916A JPWO2019175776A5 JP WO2019175776 A5 JPWO2019175776 A5 JP WO2019175776A5 JP 2020548916 A JP2020548916 A JP 2020548916A JP 2020548916 A JP2020548916 A JP 2020548916A JP WO2019175776 A5 JPWO2019175776 A5 JP WO2019175776A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- compound
- salt
- pharmaceutical
- mammal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862643467P | 2018-03-15 | 2018-03-15 | |
| US62/643,467 | 2018-03-15 | ||
| US201862666204P | 2018-05-03 | 2018-05-03 | |
| US62/666,204 | 2018-05-03 | ||
| US201862742532P | 2018-10-08 | 2018-10-08 | |
| US62/742,532 | 2018-10-08 | ||
| US201962809990P | 2019-02-25 | 2019-02-25 | |
| US62/809,990 | 2019-02-25 | ||
| PCT/IB2019/052009 WO2019175776A1 (fr) | 2018-03-15 | 2019-03-12 | Modulateurs de sting (stimulateur des gènes de l'interféron) à base de cyclopentane |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021518335A JP2021518335A (ja) | 2021-08-02 |
| JPWO2019175776A5 true JPWO2019175776A5 (fr) | 2022-03-16 |
| JP7266942B2 JP7266942B2 (ja) | 2023-05-01 |
Family
ID=66103038
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020548916A Active JP7266942B2 (ja) | 2018-03-15 | 2019-03-12 | Ｓｔｉｎｇ（インターフェロン遺伝子刺激因子）のシクロペンタン－ベースのモジュレーター |
Country Status (24)
| Country | Link |
|---|---|
| US (4) | US10538542B2 (fr) |
| EP (1) | EP3765474B1 (fr) |
| JP (1) | JP7266942B2 (fr) |
| KR (1) | KR20200131878A (fr) |
| CN (1) | CN111918871A (fr) |
| AU (1) | AU2019234043A1 (fr) |
| BR (1) | BR112020018593A2 (fr) |
| CA (1) | CA3093631C (fr) |
| CL (1) | CL2020002352A1 (fr) |
| CR (1) | CR20200382A (fr) |
| DO (1) | DOP2020000160A (fr) |
| EC (1) | ECSP20057847A (fr) |
| ES (1) | ES2923298T3 (fr) |
| IL (1) | IL277278A (fr) |
| MA (1) | MA52012A (fr) |
| MX (1) | MX2020009587A (fr) |
| NI (1) | NI202000058A (fr) |
| PE (1) | PE20210412A1 (fr) |
| PH (1) | PH12020551486A1 (fr) |
| RU (1) | RU2020130048A (fr) |
| SG (1) | SG11202008102VA (fr) |
| TW (1) | TWI741268B (fr) |
| UY (1) | UY38145A (fr) |
| WO (1) | WO2019175776A1 (fr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7098748B2 (ja) | 2017-12-20 | 2022-07-11 | インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール，ヴイ．ヴイ．アイ． | Ｓｔｉｎｇアダプタータンパク質を活性化するホスホン酸結合を有する２’３’環状ジヌクレオチド |
| AU2018392213B2 (en) | 2017-12-20 | 2021-03-04 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3' cyclic dinucleotides with phosphonate bond activating the STING adaptor protein |
| TWI833744B (zh) | 2018-04-06 | 2024-03-01 | 捷克科學院有機化學與生物化學研究所 | 3'3'-環二核苷酸 |
| TW202028179A (zh) | 2018-10-08 | 2020-08-01 | 美商普萊恩醫療公司 | 胺基酸化合物及使用方法 |
| JP2022550297A (ja) * | 2019-09-25 | 2022-12-01 | ファイザー・インク | Ｓｔｉｎｇ（インターフェロン遺伝子刺激因子）のヘテロ多環式モジュレーター |
| KR20220167275A (ko) | 2020-04-10 | 2022-12-20 | 오노 야꾸힝 고교 가부시키가이샤 | 암 치료 방법 |
| US11964978B2 (en) * | 2021-03-18 | 2024-04-23 | Pfizer Inc. | Modulators of STING (stimulator of interferon genes) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
| ES2692226T3 (es) | 2014-06-04 | 2018-11-30 | Glaxosmithkline Intellectual Property Development Limited | Dinucleótidos cíclicos como moduladores de STING |
| GB201501462D0 (en) | 2015-01-29 | 2015-03-18 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
-
2019
- 2019-03-11 US US16/297,910 patent/US10538542B2/en active Active
- 2019-03-11 TW TW108108048A patent/TWI741268B/zh not_active IP Right Cessation
- 2019-03-12 WO PCT/IB2019/052009 patent/WO2019175776A1/fr active Application Filing
- 2019-03-12 CN CN201980019494.9A patent/CN111918871A/zh active Pending
- 2019-03-12 CA CA3093631A patent/CA3093631C/fr active Active
- 2019-03-12 SG SG11202008102VA patent/SG11202008102VA/en unknown
- 2019-03-12 KR KR1020207029472A patent/KR20200131878A/ko not_active Application Discontinuation
- 2019-03-12 EP EP19717149.9A patent/EP3765474B1/fr active Active
- 2019-03-12 MX MX2020009587A patent/MX2020009587A/es unknown
- 2019-03-12 RU RU2020130048A patent/RU2020130048A/ru unknown
- 2019-03-12 ES ES19717149T patent/ES2923298T3/es active Active
- 2019-03-12 CR CR20200382A patent/CR20200382A/es unknown
- 2019-03-12 JP JP2020548916A patent/JP7266942B2/ja active Active
- 2019-03-12 PE PE2020001412A patent/PE20210412A1/es unknown
- 2019-03-12 AU AU2019234043A patent/AU2019234043A1/en not_active Abandoned
- 2019-03-12 BR BR112020018593-0A patent/BR112020018593A2/pt not_active IP Right Cessation
- 2019-03-12 MA MA052012A patent/MA52012A/fr unknown
- 2019-03-13 UY UY38145A patent/UY38145A/es not_active Application Discontinuation
- 2019-12-04 US US16/702,738 patent/US10968242B2/en active Active
-
2020
- 2020-08-25 DO DO2020000160A patent/DOP2020000160A/es unknown
- 2020-08-28 NI NI202000058A patent/NI202000058A/es unknown
- 2020-09-10 IL IL277278A patent/IL277278A/en unknown
- 2020-09-11 CL CL2020002352A patent/CL2020002352A1/es unknown
- 2020-09-12 PH PH12020551486A patent/PH12020551486A1/en unknown
- 2020-09-15 EC ECSENADI202057847A patent/ECSP20057847A/es unknown
-
2021
- 2021-03-03 US US17/190,924 patent/US20210230196A1/en not_active Abandoned
-
2023
- 2023-07-24 US US18/225,589 patent/US20230382932A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2019150305A5 (fr) | ||
| RU2014102935A (ru) | Кризотиниб для применения в лечении рака | |
| HRP20201334T1 (hr) | Kompozicije koje sadrže kombinaciju ipilimumaba i nivolumaba | |
| JP2007530526A5 (fr) | ||
| HRP20191944T1 (hr) | Soli i polimorfi od 8-fluoro-2-{4-[(metilamino)metil]fenil}-1,3,4,5-tetrahidro-6h-azepino[5,4,3-cd]indol-6-ona | |
| JP2020105190A5 (fr) | ||
| JPWO2019175776A5 (fr) | ||
| RU2008122471A (ru) | Способ лечения аномального роста клеток | |
| Brzozowa-Zasada et al. | Notch signalling pathway as an oncogenic factor involved in cancer development | |
| RU2005128791A (ru) | Лекарственные формы, содержащие ag013736 | |
| RU2014124005A (ru) | Комбинация инотузумаба озогамицина и торизела для лечения рака | |
| JP2020508302A5 (fr) | ||
| RU2006134045A (ru) | Применение антител к ctla-4 | |
| JP2009521685A5 (fr) | ||
| Xie et al. | CXCR4 promotes cisplatin-resistance of non-small cell lung cancer in a CYP1B1-dependent manner | |
| RU2014141114A (ru) | Комбинированные виды терапии с использованием ингибиторов внеклеточного домена е-кадгерина | |
| RU2020113749A (ru) | Аналоги таиланстатина | |
| Sun et al. | ARHGAP9 inhibits colorectal cancer cell proliferation, invasion and EMT via targeting PI3K/AKT/mTOR signaling pathway | |
| Klonisch et al. | Relaxin-like ligand-receptor systems are autocrine/paracrine effectors in tumor cells and modulate cancer progression and tissue invasiveness | |
| Zafrakas et al. | A rare case of renal cell carcinoma metastasizing to the uterine cervix | |
| Ni et al. | The inhibition effect of triptolide on human endometrial carcinoma cell line HEC-1B: a in vitro and in vivo studies | |
| JP2020530844A5 (fr) | ||
| Li et al. | The effects of nursing intervention on the postoperative quality of life and early compliance of patients with cervical cancer | |
| JPWO2021059136A5 (fr) | ||
| Moradi et al. | Ovarian hyperstimulation syndrome followed by ovarian torsion in premenopausal patient using adjuvant tamoxifen treatment for breast cancer |